A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Randomized controlled multi-center study with three arms including 200 patients with low risk
endometrial hyperplasia. After confirmed diagnosis the patients will receive one of the
following treatments:
1. Provera (Medroxyprogesterone (MPA)/progestin) 10 mg per oral treatment for 6 months 10
day each cycle,
2. MPA 10 mg continuously for 6 months,
3. Mirena (Levonorgestrel) impregnated IUD for 6 months.